Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.50 |
| ▸ | CCND1 | P24385 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2293305 | 0.87 | ALDH1A1 (0.56) | ALDH1A1LMNAUSP2HTTHPGD | |
| SCHEMBL5628701 | 0.86 | ALDH1A1 (0.54) | ALDH1A1LMNAUSP2HTTHPGD | |
| SCHEMBL23004866 | 0.85 | ALDH1A1 (0.62) | ALDH1A1LMNAUSP2HTTHPGD | |
| SCHEMBL9251117 | 0.84 | ALDH1A1 (0.61) | ALDH1A1LMNAUSP2HTTHPGD | |
| SCHEMBL31265581 | 0.82 | ALDH1A1 (0.68) | ALDH1A1LMNAHTTHPGDSMN1; SMN2 | |
| SCHEMBL18783927 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAUSP2HTTHPGD | |
| SCHEMBL12961822 | 0.82 | ALDH1A1 (0.53) | ALDH1A1LMNAUSP2HTTHPGD | |
| SCHEMBL3268166 | 0.81 | ALDH1A1 (0.49) | ALDH1A1LMNAUSP2HTTSMN1; SMN2 | |
| SCHEMBL23004928 | 0.80 | ALDH1A1 (0.59) | ALDH1A1LMNAUSP2HTTHPGD | |
| SCHEMBL23680052 | 0.80 | CDK4 (0.75) | ALDH1A1HTTHPGDSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024010732-A1 | SMALL MOLECULE INHIBITORS OF GLUTAMINE TRANSPORTER ASCT2 AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20230102879-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-03-30 | — | — | US | disclosed |
| US-11261201-B2 | TRNA synthetase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-01 | — | — | US | disclosed |
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-02-25 | — | — | US | disclosed |
| EP-3257842-B1 | THERAPEUTIC USE OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2020-11-18 | — | — | EP | disclosed |
| CN-104523668-B | High-purity 2- [4- (3-or 2-fluorobenzyloxy) benzylamino ] propanamides and use thereof | 纽朗制药有限公司 | 2020-06-09 | — | — | CN | disclosed |
| EP-3257842-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | Newron Pharmaceuticals S.p.A. (IT) | 2017-12-20 | — | — | EP | disclosed |
| EP-2229351-B1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2017-11-08 | — | — | EP | disclosed |
| EP-2474521-B1 | High purity degree 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides for use as medicaments and pharmaceutical formulations containing them | NEWRON PHARM SPA (IT) | 2016-08-10 | — | — | EP | disclosed |
| EP-2029524-B1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES | NEWRON PHARM SPA (IT) | 2014-11-26 | — | — | EP | disclosed |
| US-8278485-B2 | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-10-02 | — | — | US | disclosed |
| EP-2474521-A1 | High purity degree 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides for use as medicaments and pharmaceutical formulations containing them | Newron Pharmaceuticals S.p.A. (IT) | 2012-07-11 | — | — | EP | disclosed |
| US-20120157712-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-06-21 | — | — | US | disclosed |
| US-8076515-B2 | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-12-13 | — | — | US | disclosed |
| US-20100324141-A1 | HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES AND METHODS OF USE THEREOF | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-12-23 | — | — | US | disclosed |
| EP-2229351-A1 | PROCESS FOR THE PRODUCTION OF 2-Ý4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO¨PROPANAMIDES WITH HIGH PURITY DEGREE | Newron Pharmaceuticals S.p.A. (IT) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009074478-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-06-18 | — | — | WO | disclosed |
| US-20090156678-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-06-18 | — | — | US | disclosed |
| EP-2029524-A1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES | Newron Pharmaceuticals S.p.A. (IT) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007147491-A1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLU0R0BENZYL0XY) BENZYLAMIN0] PROPAN AMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | ALDH1A1 2254/4885LMNA 3398/4885USP2 2216/4885 |
| US-20090156678-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | PTMA, PSMB2, PDGFRA | ALDH1A1 593/4885LMNA 3445/4885USP2 669/4885 |
| US-20230102879-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | ALDH1A1 2254/4885LMNA 3398/4885USP2 2216/4885 |
| US-20100324141-A1 | HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES AND METHODS OF USE THEREOF | PDE7A, PDE8B, PDE9A | ALDH1A1 150/4885LMNA 1531/4885USP2 1699/4885 |
| US-20120157712-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | PTMA, PSMB2, PDGFRA | ALDH1A1 593/4885LMNA 3445/4885USP2 669/4885 |
| US-11261201-B2 | TRNA synthetase inhibitors | TRMT1, AARS1, GARS1 | ALDH1A1 2254/4885LMNA 3398/4885USP2 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.